



**Key Data Presentations (Pfizer-Sponsored and Collaborative Research Studies) at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018**

*The embargo on all data will lift on Wednesday, May 16, at 5:00 p.m. EDT.*

**Avelumab:**

**(Abstract 9507) Two-Year Efficacy and Safety Update from JAVELIN Merkel 200 Part A: A Registrational Study of Avelumab in Metastatic Merkel Cell Carcinoma Progressed on Chemotherapy.** Nghiem P. Monday, June 4. Session Type: Oral. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Arie Crown Theater.

**(Abstract 9008) Avelumab (anti-PD-L1) in Combination with Crizotinib or Lorlatinib in Patients with Previously Treated Advanced NSCLC: Phase Ib Results from the JAVELIN Lung 101.** Shaw A. Friday, June 1. Session Type: Oral. Presentation Time: 4:30 p.m. – 6:00 p.m. CDT. Location: Hall D1.

**(Abstract 9090) Avelumab (anti-PD-L1) in Patients with Platinum-Treated Advanced NSCLC: 2.5-Year Follow-Up from the JAVELIN Solid Tumor Trial.** Rajan A. Sunday, June 3. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 413.

**(Abstract 9537) Second-Line Avelumab Treatment of Patients (Pts) with Metastatic Merkel Cell Carcinoma (mMCC): Experience from a Global Expanded Access Program (EAP).** Walker J. Monday, June 4. Session Type: Poster Session. Presentation Time: 1:15 p.m. – 4:45 p.m. CDT. Location: Hall A. Poster Board: 364.

**(Abstract 3057) Association of Efficacy and Adverse Events of Special Interest of Avelumab in the JAVELIN Solid Tumor and JAVELIN Merkel 200 Trials.** Kelly K. Monday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 271.

**(Abstract 4544) SPEAR-Bladder (Study Informing Treatment Pathway Decision in Bladder Cancer): First-Through Third-Line Time to Treatment Failure in the US.** Doshi G. Saturday, June 2. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 370.

**Bosutinib:**

**(Abstract 7002) Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: 24-Month Follow-Up.** Cortes JE. Saturday, June 2. Session Type: Oral. Presentation Time: 3:00 p.m. – 6:00 p.m. CDT. Location: E450.

**(Abstract 7062) Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors (TKIs) in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Leukemia: Phase I/II Study Update.** Gambacorti-Passerini C. Saturday, June 2. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 122.



### Crizotinib:

**(Abstract 9062) Crizotinib in Patients (Pts) with MET-Amplified Non-Small Cell Lung Cancer (NSCLC): Updated Safety and Efficacy Findings from a Phase I Trial.** Camidge DR. Sunday, June 3. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 385.

### Dacomitinib:

**(Abstract 9004) Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced NSCLC (ARCHER 1050): Final Overall Survival Analysis.** Mok T. Monday, June 4. Session Type: Oral. Presentation Time: 3:00 p.m. – 6:00 p.m. CDT. Location: Hall B1.

### Enzalutamide:

**(Abstract 5043) Association Between Health-Related Quality of Life (HRQoL) and Clinical Outcomes in Non-Metastatic Castration-Resistant Prostate Cancer (M0 CRPC): Results from the PROSPER Study.** Attard G. Saturday, June 2. Session Type: Poster Session. Presentation Time: 1:15 p.m. – 4:45 p.m. CDT. Location: Hall A. Poster Board: 270.

**(Abstract 5010) Health-Related Quality of Life (HRQoL) Deterioration and Pain Progression in Men with Non-Metastatic Castration-Resistant Prostate Cancer (M0 CRPC): Results from the PROSPER Study.** Attard G. Saturday, June 2. Session Type: Poster Discussion Session. Presentation Time: 4:45 p.m. – 6:00 p.m. CDT. Location: S406. Poster Board: 237.

### Glasdegib:

**(Abstract TPS7073) Phase III, Randomized, Placebo-Controlled Trials Evaluating Glasdegib in Combination with Intensive or Nonintensive Chemotherapy in Patients with Untreated Acute Myeloid Leukemia.** Cortes JE. Monday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 133a.

### Inotuzumab:

**(Abstract 7028) Inotuzumab Ozogamicin (InO) Treatment in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Analysis from INO-VATE by Bone Marrow Blast Percentage (BMB%).** Advani A. Monday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 88.

**(Abstract 7029) Extensive Safety Profile of Inotuzumab Ozogamicin (InO) in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Patients Enrolled in the Phase III INO-VATE Trial.** Cassaday R. Monday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 89.

**(Abstract 7030) Outcomes with Inotuzumab Ozogamicin (InO) in Patients with Philadelphia Chromosome-Positive (Ph+) Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL).** Stock W. Monday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 90.



**(Abstract 7013) Impact of Minimal Residual Disease (MRD) Status in Clinical Outcomes of Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (InO) in the Phase III INO-VATE Trial.** Jabbour E. Monday, June 4. Session Type: Poster Discussion Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Discussion Time: 11:30 a.m. – 12:45 p.m. Location: E450. Poster Board: 73.

#### Lorlatinib:

**(Abstract 9032) Lorlatinib in Patients (Pts) With Previously Treated ALK+ Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Efficacy and Safety.** Besse B. Sunday, June 3. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 355.

#### Palbociclib:

**(Abstract 1001) Genetic Landscape of Resistance to CDK4/6 Inhibition in Circulating Tumor DNA (ctDNA) Analysis of the PALOMA3 Trial of Palbociclib and Fulvestrant Versus Placebo and Fulvestrant.** Turner N. Sunday, June 3. Session Type: Oral. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Hall D2.

**(Abstract 6008) Multicenter Phase II Trial of Palbociclib, a Selective Cyclin Dependent Kinase (CDK) 4/6 Inhibitor, and Cetuximab in Platinum-Resistant HPV Unrelated (-) Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC).** Adkins D. Sunday, June 3. Session Type: Oral. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: E451.

**(Abstract 1023) Treatment Effect of Palbociclib (PAL) Plus Endocrine Therapy (ET) by Prognostic and Intrinsic Subtype: A Joint Analysis of PALOMA2 and PALOMA3.** Finn RS. Saturday, June 2. Session Type: Poster Discussion Session. Presentation Time: 1:15 p.m. – 2:30 p.m. CDT. Location: Hall D1. Poster Board: 104.

**(Abstract 1060) Hematologic Adverse Events Following Palbociclib (PAL) Dose Reduction in Patients (Pts) with Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor-2–Negative (HER2–) Advanced Breast Cancer (ABC): Pooled Analysis from Randomized Phase II and III Studies.** Verma S. Saturday, June 2. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 141.

#### Sunitinib:

**(Abstract 4565) Disease-Free Survival in Patients at Highest Risk of Recurrent Renal Cell Carcinoma in S-TRAC.** Ravaud A. Saturday, June 2. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 391.

**(Abstract 4562) Neutrophil-to-Lymphocyte Ratio as a Potential Prognostic Factor of Disease-Free Survival in High-Risk Renal Cell Carcinoma: Analysis of the S-TRAC Trial.** Patel A. Saturday, June 2. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 388.

#### Talazoparib:

**(Abstract TPS5091) TALAPRO-2: A 2-Part, Placebo-Controlled Phase III Study of Talazoparib (TALA) With Background Enzalutamide (ENZA) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) With DNA**



**Damage Repair Deficiencies.** Agarwal NR. Saturday, June 2. Session Type: Poster Session. Presentation Time: 1:15 p.m. – 4:45 p.m. CDT. Location: Hall A. Poster Board: 315b

**(Abstract 1070) Analysis of Germline BRCA1/2 Mutated (gBRCAmut) Hormone Receptor-Positive (HR+) and Triple Negative Breast Cancer (TNBC) Treated with Talazoparib (TALA).** Eiermann W. Saturday, June 2. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 151.

**(Abstract 1069) EMBRACA: Efficacy Outcomes in Clinically Relevant Subgroups Comparing Talazoparib (TALA), an Oral Poly ADP Ribose Polymerase (PARP) Inhibitor, to Physician's Choice of Therapy (PCT) in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.** Rugo HS. Saturday, June 2. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 150.

**(Abstract 2548) NCI9782: A Phase I Study of Talazoparib in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors.** Turk A. Monday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 374.

#### Early-Pipeline Assets:

##### *Anti-PTK7 (PF-06647020):*

**(Abstract 5565) PF-06647020 (PF-7020), an Antibody-Drug Conjugate (ADC) Targeting Protein Tyrosine Kinase 7 (PTK7), in Patients (Pts) with Advanced Solid Tumors: Results of a Phase I Dose Escalation and Expansion Study.** Sachdev JC. Monday, June 4. Session Type: Poster Session. Presentation Time: 1:15 p.m. – 4:45 p.m. CDT. Location: Hall A. Poster Board: 292.

**(Abstract 2574) Clinical Pharmacology Assessment of PF-06647020 (PF-7020), an Antibody-Drug Conjugate (ADC) Targeting Protein Tyrosine Kinase 7 (PTK7), in Adult Patients (Pts) with Advanced Solid Tumors.** Xuan D. Monday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 400.

##### *Gedatolisib:*

**(Abstract 1040) Phase Ib Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy (ET) in Women with Estrogen Receptor (ER) Positive (+) Metastatic Breast Cancer (MBC) (B2151009).** Forero A. Saturday, June 2. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: 121.

#### Biosimilars:

##### **(Abstract 109)**

**A Comparative Clinical Study of PF-06439535, a Candidate Bevacizumab Biosimilar, and Reference Bevacizumab, in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer.** Socinski M. Monday, June 4. Session Type: Oral. Presentation Time: 9:45 a.m. – 11:15 a.m. CDT. Location: Hall D1.

###